Assessment of efficacy and toxicity of the fractionated radiotherapy with stereotactic body radiosurgery boost in prostate cancer patients: pilot clinical study results.

Hubert Urbanczyk; Leszek Hawrylewicz; Grzegorz G?owacki; Justyna Rembak-Szynkiewicz; Wojciech Majewski

Volume : VII, Issue : I, January - 2018

Assessment of efficacy and toxicity of the fractionated radiotherapy with stereotactic body radiosurgery boost in prostate cancer patients: pilot clinical study results.

Hubert Urbanczyk, Leszek Hawrylewicz, Grzegorz G Owacki, Justyna Rembak Szynkiewicz, Wojciech Majewski

Abstract :

Background: Prostate cancer (PC) represents one of the most common malignancies in men. Radiotherapy (RT) has been used more often therapy. Stereotactic body radiosurgery (SBRS) has become used, as monotherapy. The effects of SBRS boost, added to RT have not been extensively studied.

Purpose: to prospectively assess efficacy and toxicity of the hypofractionated SBRS boost in RT, in prostate cancer patients.

Methods and Materials: RT of the prostate up to 50 Gy, with additional hypofractionated SBRS, with fractionated dose of 7 Gy, twice were used. 22 patients, age 45 to 80 years with localized prostate adenocarcinoma were included. The median observation time was 60 months (23 – 66).

Results: No patient in this study had PC recurrence. There was no unacceptable toxicity.

Conclusions: Conventional radiotherapy, combined with SBRS boost, appears to be safe and efficient in patients with localized prostate cancer. These results justify initiation of the randomized trial.